Peter G. Kleinhenz

Peter Kleinhenz is an accomplished life sciences leader and successful venture capitalist. Mr. Kleinhenz most recently served as the CFO and CBO at Myonexus Therapeutics, Inc, a clinical stage gene-therapy company pioneering in limb girdle muscular dystrophy treatments, which was acquired by Sarepta Therapeutics in April 2019. Previously, Mr. Kleinhenz was Partner and Managing Director at Fletcher Spaght Ventures and CID Capital, Inc. and served in numerous board and advisory roles for growing life science companies. Peter’s leadership experience spans business development, financial strategy and executive leadership at companies including Battelle Memorial Institute; Progenics Inc., and Neoprobe Corporation. He co-founded the MidAmerica Health Innovation Network and has served as a board member of BioOhio for over 20 years. Peter received a bachelor’s degree from Loyola University of Chicago, and his MBA from Case Western Reserve University.